Oligopeptide for treating solid tumors and leukaemia and application thereof

A leukemia and short peptide technology, applied in the field of biotechnology and medicine, can solve the problems of low activity and poor therapeutic effect

Inactive Publication Date: 2014-12-24
陈秀定
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0022] In the prior art, CN 101497653 B discloses a short peptide that inhibits the growth of solid tumors and leukemia cancer cells, but the short peptide still has the disadvantages of poor therapeutic effect and relatively low activity in use. Therefore, the inventor here Based on the research and development of the new polypeptide of the present application, it has a better therapeutic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oligopeptide for treating solid tumors and leukaemia and application thereof
  • Oligopeptide for treating solid tumors and leukaemia and application thereof
  • Oligopeptide for treating solid tumors and leukaemia and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1 Synthesis of peptide

[0045] The preparation method of the short peptide adopts a chemical synthesis method, that is, a very mature solid-phase peptide synthesis method well known in the art, and either the Boc method or the Fmoc method can be used. The specific method is to couple the protected amino acids to an inert solid phase carrier one by one, and then use a strong acid to cleave the peptide chain from the carrier while removing the side chain protection.

[0046] The amino acid sequence of the synthesized short peptide is consistent with the sequence, indicating that the synthesis is successful.

Embodiment 2

[0047] Example 2 Determination of peptide function

[0048] 1. Tests to inhibit liver cancer cells

[0049] The human hepatocarcinoma cell line Hepg2 cells were cultured in RPMI 1640 medium containing 10% newborn calf serum, and planted into 96-well cell plates at a cell density of 5×105 / well. After 24 hours, the short peptide SEQ of the present invention ID NO: 1-14 and control peptides were added to the cell culture plate at different concentrations. The same volume of PBS was used as the control group. After 72 hours, the survival rate of living cells was tested by the MTT method. The administration group was compared with the control group. Obtain the inhibition rate of liver cancer cells.

[0050] 2. The human acute myeloid leukemia cell line HL60 cells are cultured in RPMI 1640 medium containing 10% newborn calf serum, and after planting them into a 24-well cell plate at a cell density of 106 / well, the present invention involves The short peptide SEQ ID NO: 1-14 and the contr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an oligopeptide for treating solid tumors and leukaemia and application thereof. The sequence is SEQ ID NO:1-15. The oligopeptide can be used for treating leukaemia caused by nonsolid tumor human medullary system various pathology hyperplasia and various cancers caused by human solid tumor cancer cell proliferation.

Description

Technical field [0001] The present invention belongs to the field of biotechnology and medicine, and more specifically relates to short peptides for treating solid tumors and leukemia and their applications. Background technique [0002] Leukemia is a malignant clonal disease of hematopoietic stem cells. Clonal leukemia cells proliferate and accumulate in bone marrow and other hematopoietic tissues, and infiltrate other tissues and organs, and normal hematopoiesis is inhibited due to mechanisms such as uncontrolled proliferation, differentiation failure, and obstructed apoptosis. Clinically, anemia, bleeding, infection, fever, liver, spleen, lymph node enlargement and bone pain can be seen in different degrees. According to reports, the incidence of leukemia in various regions of our country occupies the sixth place among various tumors. [0003] According to the priority of onset, it can be divided into acute and chronic leukemia. The differentiation of acute leukemia cells is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K7/08A61K38/08A61K38/10A61P35/00A61P35/02
Inventor 陈秀定
Owner 陈秀定
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap